MODD Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Modular Medical's net margin of 12.06%. Modular Medical's return on equity of -- beat Electromed's return on equity of 16.57%.

Modular Medical has a consensus price target of $8.00, signalling upside risk potential of 838.09%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 88.3%. Given that Modular Medical has higher upside potential than Electromed, analysts believe Modular Medical is more attractive than Electromed.

Modular Medical has a beta of -4.845, which suggesting that the stock is 584.542% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Modular Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Modular Medical pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Modular Medical quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Modular Medical's net income of -$4.8M is lower than Electromed's net income of $1.9M. Notably, Modular Medical's price-to-earnings ratio is -- while Electromed's PE ratio is 24.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Modular Medical is -- versus 2.87x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -- compared to Modular Medical's net margin of -14.17%. Modular Medical's return on equity of -- beat IRIDEX's return on equity of -218.69%.

Modular Medical has a consensus price target of $8.00, signalling upside risk potential of 838.09%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 104.08%. Given that Modular Medical has higher upside potential than IRIDEX, analysts believe Modular Medical is more attractive than IRIDEX.

Modular Medical has a beta of -4.845, which suggesting that the stock is 584.542% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

Modular Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Modular Medical pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Modular Medical quarterly revenues are --, which are smaller than IRIDEX quarterly revenues of $11.9M. Modular Medical's net income of -$4.8M is lower than IRIDEX's net income of -$1.7M. Notably, Modular Medical's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Modular Medical is -- versus 0.33x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Modular Medical's net margin of -35.24%. Modular Medical's return on equity of -- beat Myomo's return on equity of -38.11%.

Modular Medical has a consensus price target of $8.00, signalling upside risk potential of 838.09%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 191%. Given that Modular Medical has higher upside potential than Myomo, analysts believe Modular Medical is more attractive than Myomo.

Modular Medical has a beta of -4.845, which suggesting that the stock is 584.542% less volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Modular Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Modular Medical pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Modular Medical quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.8M. Modular Medical's net income of -$4.8M is lower than Myomo's net income of -$3.5M. Notably, Modular Medical's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Modular Medical is -- versus 3.13x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Modular Medical's net margin of -77.93%. Modular Medical's return on equity of -- beat Stereotaxis's return on equity of -174.6%.

Modular Medical has a consensus price target of $8.00, signalling upside risk potential of 838.09%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 117.39%. Given that Modular Medical has higher upside potential than Stereotaxis, analysts believe Modular Medical is more attractive than Stereotaxis.

Modular Medical has a beta of -4.845, which suggesting that the stock is 584.542% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

Modular Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Modular Medical pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Modular Medical quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $7.5M. Modular Medical's net income of -$4.8M is higher than Stereotaxis's net income of -$5.8M. Notably, Modular Medical's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Modular Medical is -- versus 6.49x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.